UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

(Rule 13d-102)

Under the Securities Exchange Act of 1934

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2

 

(Amendment No. 6)*

 

 

NeuroMetrix, Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

641255203

(CUSIP Number)

 

December 31, 2011

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

£ Rule 13d-1(b)

 

£ Rule 13d-1(c)

 

S Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP NO.  641255104

 

 

1	NAME OF REPORTING PERSONS   Shai N. Gozani, M.D., Ph.D.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)   ¨ (b)   ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION            United States

NUMBER OF	5	SOLE VOTING POWER   212,203
SHARES BENEFICIALLY OWNED BY	6	SHARED VOTING POWER   0
EACH REPORTING PERSON	7	SOLE DISPOSITIVE POWER   212,203
WITH	8	SHARED DISPOSITIVE POWER   0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON            212,203 shares
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨          Not applicable.
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)            5.4% (based on 3,904,320 shares outstanding on December 31, 2011)
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)            IN

 

 

 

Item 1	(a).	Name of Issuer
		NeuroMetrix, Inc.
Item 1	(b).	Address of Issuer’s Principal Executive Offices
		62 Fourth Avenue
		Waltham, MA  02451
Item 2	(a).	Name of Person Filing
		Shai N. Gozani, M.D., Ph.D.
Item 2	(b).	Address of Principal Business Office or, if None, Residence
		Shai N. Gozani, M.D., Ph.D.
		c/o NeuroMetrix, Inc.
		62 Fourth Avenue
		Waltham, MA  02451
Item 2	(c).	Citizenship
		United States
Item 2	(d).	Title of Class of Securities
		Common Stock, par value $0.0001 per share
Item 2	(e).	CUSIP Number
		641255203
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	(a)	[    ]	Broker or dealer registered under Section 15 of the Act.
	(b)	[    ]	Bank as defined in Section 3(a)(6) of the Act.
	(c)	[    ]	Insurance company as defined in Section 3(a)(19) of the Act.
	(d)	[    ]	Investment company registered under Section 8 of the Investment Company Act of 1940.
	(e)	[    ]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
	(f)	[    ]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
	(g)	[    ]	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
	(h)	[    ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
	(i)	[    ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
	(j)	[    ]	A non-U.S. institution in accordance with Section 13d-1(b)(1)(ii)(J).
	(k)	[    ]	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
	filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: __________________

  

Item 4.	Ownership
	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)          Amount beneficially owned:

 

 

The aggregate number of shares beneficially owned by Shai N. Gozani, M.D., Ph.D. as of December 31, 2011 is 212,203. Dr. Gozani directly owns 156,089 shares of the Issuer’s common stock and options to purchase 56,114 shares of common stock which are or will be immediately exercisable within 60 days of December 31, 2011.

 

(b)        Percent of class:

 

The aggregate percent of the class beneficially owned by Dr. Gozani is 5.4%.

The information provided under this section is based on 3,904,320 shares outstanding on December 31, 2011.

 

(c)        Number of shares as to which such person has:

 

(i)        Sole power to vote or to direct the vote: 212,203

 

(ii)       Shared power to vote or to direct the vote: 0

 

(iii)      Sole power to dispose or to direct the disposition of: 212,203

 

(iv)      Shared power to dispose or to direct the disposition of: 0

 

Item 5.	Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     [   ].
	Not applicable.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person
	Not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
	Not applicable.
Item 8.	Identification and Classification of Members of the Group
	Not applicable.
Item 9.	Notice of Dissolution of Group
	Not applicable.
Item 10.	Certifications
	Not applicable.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	February 13, 2012 _____________________________ (Date)
	/s/ Shai N. Gozani, M.D., Ph.D. _____________________________ (Signature)
	Shai N. Gozani, M.D., Ph.D. _____________________________ (Name)

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

 

Attention:

Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)